文献速递胸部肿瘤

靶向测序基因组评分预测免疫治疗临床获益

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
PubMed 文献 · Eur J Cancer · 2019-09-04

该研究纳入248例接受抗PD-1/PD-L1治疗的晚期非小细胞肺癌患者,采用靶向测序380个癌症相关基因获取肿瘤突变负荷(TMB)和体细胞拷贝数改变(SCNA),并结合PD-L1表达构建综合预测评分。结果显示联合评分较单一指标提高了免疫治疗反应预测准确性,靶向测序可高效获取TMB和SCNA。

要点

  • 靶向测序获取的TMB和SCNA与全外显子测序结果相关性良好。
  • TMB、SCNA和PD-L1联合评分较单一指标提高预测准确性。
  • 靶向测序可高效获取肿瘤分子特征用于免疫治疗获益预测。

核心结论

  • TMB、SCNA和PD-L1均为免疫检查点抑制剂(ICI)生物标志物,联合所有因素较单一因素提高ICI反应预测准确性。

研究设计与样本

  • 研究纳入248例接受抗PD-1/PD-L1治疗的晚期非小细胞肺癌患者,随访至少6个月,肿瘤组织用于PD-L1染色、380个癌症相关基因靶向测序和全外显子测序(WES)。

主要发现

  • 靶向测序获得的TMB在部分缓解(PR)患者中高于疾病进展(PD)/疾病稳定(SD)患者(P = 0.01),在持久临床获益(DCB)患者中高于非持久获益(NDB)患者(P = 0.05)。
  • SCNA在PR患者中低于PD/SD患者(P = 0.02),在DCB患者中低于NDB患者(P = 0.02)。
  • 靶向测序TMB和SCNA与WES结果相关性分别为r = 0.87和r = 0.62。
  • 在本队列中,联合TMB、SCNA和PD-L1的新预测评分AUC = 0.71,而TMB单独AUC = 0.63、SCNA单独AUC = 0.52、PD-L1单独AUC = 0.57;其他队列验证集也显示新模型预测评分改善。

临床怎么用

  • 可利用靶向测序获取TMB和SCNA,结合PD-L1表达综合评估免疫治疗获益可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Immune checkpoint inhibitors (ICIs) induce durable responses, but their clinical benefits apply to only a subset of patients. Therefore, precisely predicting a patient's response before ICI treatment is crucial. METHODS: A total of 248 patients with anti-Programmed cell death protein 1/Programmed death-ligand 1 (PD1/PD-L1)-treated advanced non-small cell lung cancer were enrolled, and clinical outcomes were collected with a minimum 6-month follow-up period. Tumour tissues were used for PD-L1 staining, targeted sequencing of 380 cancer-related genes and whole-exome sequencing (WES). RESULTS: The tumour mutation burden (TMB) obtained from targeted sequencing was higher among patients with a partial response (PR) than those with progressive disease (PD)/stable disease (SD) (P = 0.01) and in those with durable clinical benefit (DCB) than nondurable benefit (NDB) (P = 0.05). The somatic copy number alteration (SCNA) was lower in patients with a PR than those with PD/SD (P = 0.02) and in those with DCB than NDB (P = 0.02). The accuracy of the TMB and SCNA results from the targeted sequencing was confirmed by testing the correlation of the TMB and SCNA results from the targeted sequencing against those results from WES (r = 0.87, r = 0.62, respectively). To improve prediction score, TMB, SCNA and PD-L1 were integrated. New prediction scores reached Area under the ROC Curve (AUC) = 0.71 from TMB (AUC = 0.63), SCNA (AUC = 0.52) or PD-L1 (AUC = 0.57) with our cohort, and validation set from other cohorts also showed improved prediction scores with our new model. CONCLUSION: We report TMB, SCNA and PD-L1 as ICI biomarkers. Combining all these factors improved the prediction accuracy of ICI response compared with using individual factors. Tumour molecular features, TMB and SCNA, were efficiently obtained by targeted sequencing.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kim HS, Cha H, Kim J, et al. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Eur J Cancer. 2019. PMID: 31493723. doi:10.1016/j.ejca.2019.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。